BC
MNTA

Brinker Capital’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Brinker Capital’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19,110
Closed -$503K – 1014
2018
Q3 		$503K Buy
19,110
+1,554
+9% +$42K 0.02% 717
2018
Q2 		$359K Buy
17,556
+1,177
+7% +$25.3K 0.01% 814
2018
Q1 		$297K Buy
16,379
+977
+6% +$16.3K 0.01% 855
2017
Q4 		$215K Sell
15,402
-5,427
-26% -$73.4K 0.01% 939
2017
Q3 		$385K Sell
20,829
-214
-1% -$3.58K 0.02% 745
2017
Q2 		$356K Sell
21,043
-371
-2% -$5.65K 0.02% 584
2017
Q1 		$286K Buy
21,414
+615
+3% +$9.63K 0.01% 797
2016
Q4 		$313K Buy
+20,799
New +$275K 0.02% 567

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Brinker Capital's MNTA Position: Q4 2018 in Review

Brinker Capital sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2018, closing a stake of 19,110 shares — an estimated $503K sold.

Brinker Capital first reported a position in MNTA in Q4 2016 and held it in 8 quarters. The position peaked at $503K in Q3 2018. 158 funds tracked by Wall St. Rank hold MNTA as of Q4 2018.

  • Brinker Capital reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Brinker Capital sold 19,110 Momenta Pharmaceuticals, Inc. shares in Q4 2018, an estimated $503K.
  • Brinker Capital first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2016 and held it in 8 quarters.
  • Brinker Capital's Momenta Pharmaceuticals, Inc. position peaked at $503K in Q3 2018.
  • 158 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2018.

Based on Brinker Capital's 13F filing for Q4 2018, filed 14 Feb 2019.